Subjective response to antipsychotics in schizophrenic patients: Clinical implications and related factors

Schizophrenia Research

Volumn 41, Issue 2, 2000, Pages 349-355

  Garcia Cabeza I ^a   Sanz Amador, M ^a   Arango Lopez C ^b   Gonzalez De Chavez M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Schizophrenia; Subjective response

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ARTICLE; DRUG EFFICACY; DRUG RESPONSE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MOTIVATION; MULTIPLE REGRESSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SOCIAL ASPECT;

ACTIVITIES OF DAILY LIVING; ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT ADMISSION; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SICK ROLE; TREATMENT OUTCOME;

EID: 0033969937     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00079-1     Document Type: Article

References (33)

1. Awad A.G., Hogan T.P. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 9:1985;585-589.
2. Awad A.G. Subjective response to neuroleptics in schizophrenia. Schizophr. Bull. 19:1993;609-618.
3. Awad A.G., Hogan T.P., Voruganti L.N.P., Heslegrave R.J. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int. Clin. Psychopharmacol. 10:(Suppl. 3):1995;123-132.
4. Awad A.G., Voruganti L.N.P., Heslegrave R.J. Clinical correlates of neuroleptic dysphoria during antipsychotic drug therapy of schizophrenia. Proc. 34th Annual Meeting of American College of Neuropsychopharmacology, San Juan de Puerto Rico. 1995;134.
5. Bech P., Kastrup M., Rafaeken O.J. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr. Scand. 73:(Suppl. 326):1988.
6. Belmaker R.H., Wald D. Haloperidol in normals. Br. J. Psychiatry. 131:1977;222-223.
7. Birchwood M., Smith J., Drury V., Healy J., Macmillan F., Slade M. A self-report insight scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatr. Scand. 89:1994;62-67.
8. Browne S., Garavan J., Gervin M., Roe M., Larkin C., O'Callaghan E.J. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J. Nerv. Ment. Dis. 186:1998;74-78.
9. Bruun R.D. Subtle and unrecognized side-effects of neuroleptic treatment in children with Tourette's disorder. Am. J. Psychiatry. 145:1988;621-624.
10. Caine E.D., Polinsky R.J. Haloperidol induced dysphoria in patients with Tourette's syndrome. Am. J. Psychiatry. 136:1979;1216-1217.
11. Cole J.O., Bonato R., Goldberg S.C. Non-specific factors in the drug therapy of schizophrenic patients. Rickels K. Non-specific Factors in Drug Therapy. 1968;115-127 Charles C. Thomas, Springfield, IL.
12. Endicott J., Spitzer R.L., Fleiss J.L., Cohen J. The global assessment scale. Arch. Gen. Psychiatry. 33:1976;766-771.
13. Evans F.J. The placebo response in pain reduction. Advances in Neurology. Bonica J.J. Pain. Vol. 4:1974;289-296 Raven, New York.
14. Gebhard R. Veränderungen der subjektiven befindlichkeit psychotischer patienten unter neuroleptischer therapy. Pharmacopsychiatry. 5:1972;295-300.
15. Hirsch S.R., Jolly A.G. The dysphoric syndrome in schizophrenia and its implications for relapse. Br. J. Psychiatry. 155:(Suppl. 5):1989;46-50.
16. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 13:1983;177-183.
17. Hogan T.P., Awad A.G. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol. Med. 22:1992;347-352.
18. Johnson D.A.W. Studies of depressive symptoms in schizophrenia. Br. J. Psychiatry. 139:1981;89-101.
19. Kemp R., David A. Psychological predictors of insight and compliance in psychotic patients. Br. J. Psychiatry. 169:1996;444-450.
20. Lehmann H.E. Individual differences in response to pharmacotherapy. Wittenborn J.R., May P.R.A. Prediction to Response to Pharmacotherapy. 1966;18-42 Charles C. Thomas, Springfield, IL.
21. Lingjaerde O., Ahifors U., Bech P., Dencker S., Elgen K. The UKU side effect rating scale. Acta Psychiatr. Scand. 34:(Suppl. 76):1987;1-100.
22. May P.R.A., Van Putten T., Yale C., Potepan P., Jenden D.J., Fairchild M.D., Goldstein M.J., Dixon W.J. Predicting individual responses to drug treatment in schizophrenia. J. Nerv. Ment. Dis. 126:1976;177-183.
23. Naber D., Holzbach R., Perro C., Hippius H. Clinical management of clozapine patients in relation to efficacy and side-effects. Br. J. Psychiatry. 160:(Suppl. 17):1992;54-59.
24. Naber D. A self-rating to measure subjective effects of neuroleptic drug, relationships to psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol. 10:(Suppl. 3):1995;133-138.
25. Rickels K. Non-specific Factors in Drug Therapy. 1968;Charles C. Thomas, Springfield, IL.
26. Sarwer-Foner G.J. On the mechanism of action of neuroleptic drugs: a theoretical psycho-dynamic explanation. Recent Adv. Biol. Psychiatry. 6:1963;217-232.
27. Singh M.M., Smith J.M. Kinetics and dynamics of response to haloperidol in acute schizophrenia: its relationship to autonomic arousal and prognosis: a longitudinal study of the therapeutic process. Compr. Psychiatry. 14:1973;178-179.
28. Singh M.M., Kay S.R. Dysphoric response to neuroleptic treatment in schizophrenia: Its relationship to autonomic arousal and prognosis. Biol. Psychiatry. 14:1979;277-294.
29. Van Putten T., May P.R.A. Subjective response as a predictor of outcome in pharmacotherapy. Arch. Gen. Psychiatry. 35:1978;477-480.
30. Van Putten T., May P.R.A., Marder S.R. Subjective response to thiothixene and chlorpromazine. Psychopharmacol. Bull. 16:1980;36-38.
31. Van Putten T., May P.R.A., Marder S.R., Wittman L.A. Subjective response to antipsychotic drugs. Arch. Gen. Psychiatry. 38:1981;187-190.
32. Voruganti L.N.P., Heslegrave R.J., Awad A.G. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J. Nerv. Ment. Dis. 7:1997;463-465.
33. Weiden P., Rapkin B., Mott T., Zygmunt A., Goldman D., Horvitz M., Frances A. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr. Bull. 20:1994;297-310.